Seres Therapeutics, Inc. (MCRB) Investor Relations Documents

Seres Therapeutics, Inc. (MCRB) investor relations documents from the company's IR site: 13 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releaseSeres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action
2026-07-08Press releaseSeres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related En
2026-06-25Press releaseSeres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155
2026-06-05Press releaseSeres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projec
2026-05-12Press releaseSeres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-05Press releaseSeres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-04Press releaseSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation
2026-04-20Press releaseSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
2026-04-09Press releaseSeres Therapeutics to Present at CARB-X Investor Day
2026-03-12Press releaseSeres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-02-12Press releaseSeres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
Press releaseSeres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit
Press releaseSeres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to

MCRB overview · MCRB earnings · MCRB financials · MCRB KPIs · MCRB ownership · MCRB peers · MCRB filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.